Quince Therapeutics, Inc. announced the presentation of two posters at the 2024 International Congress for Ataxia Research (ICAR). The presentations featured data from the company's prior Phase 3 ATTeST clinical trial of its lead asset, EryDex, for the treatment of Ataxia-Telangiectasia (A-T).
The ATTeST trial, formally known as Ataxia-Telangiectasia Trial with the EryDex System, previously evaluated EryDex in patients with A-T. Presenting this data at a major international congress underscores the company's commitment to sharing scientific findings and engaging with the global A-T research community.
This continued presentation of data from the ATTeST study contributes to the growing body of evidence supporting EryDex. It helps to further establish the profile of the drug as the company progresses with its pivotal Phase 3 NEAT clinical trial.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.